---
title: "Alligator Bioscience Publishes 2025 Annual Report Highlighting Cancer Immunotherapy Progress"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280650217.md"
description: "Alligator Bioscience Publishes 2025 Annual Report Highlighting Cancer Immunotherapy Progress"
datetime: "2026-03-26T14:28:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280650217.md)
  - [en](https://longbridge.com/en/news/280650217.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280650217.md)
generator: "portal-rs"
---

# Alligator Bioscience Publishes 2025 Annual Report Highlighting Cancer Immunotherapy Progress

Alligator Bioscience Publishes 2025 Annual Report Highlighting Cancer Immunotherapy Progress

### Related Stocks

- [APTOF.US](https://longbridge.com/en/quote/APTOF.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [AADI.US](https://longbridge.com/en/quote/AADI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Biotech Stocks Facing FDA Decision In September 2026](https://longbridge.com/en/news/297065559.md)
- [Aptose Presents 86% CRc and 86% MRD-negativity in TUSCANY AML Triplet Trial](https://longbridge.com/en/news/289779990.md)
- [“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z](https://longbridge.com/en/news/297407072.md)
- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**